AbCellera Readies 80-Patient ABCL635 Phase II After $1B Platform Build
AbCellera Biologics holds $700 million in cash and committed funding with a $120 million annual run rate after completing a new GMP facility and investing roughly $1 billion in its antibody platform. Its lead program, ABCL635 for menopausal hot flashes, enters an 80-patient Phase II trial expected after Labor Day.
1. Strategic Shift to Pipeline
After investing roughly $1 billion over 13 years, AbCellera is transitioning from a partner-fee model to a pipeline-driven biotech, focusing on internally selected antibody therapeutics and supporting development with a newly completed GMP facility.
2. ABCL635 Phase II Trial Design
Lead program ABCL635 targets NK3R to treat menopausal vasomotor symptoms; early data show clean safety, PK alignment and biomarker engagement, and an 80-patient, triple-blinded, 2:1 randomized Phase II trial is slated for Q3 completion, expected after Labor Day.
3. Market Opportunity and Differentiation
The addressable market includes about 12 million U.S. women with moderate-to-severe hot flashes, with roughly one in five unable to use or tolerate hormone therapy; half of women prefer monthly auto-injectors over daily pills, and early research suggests ABCL635 could offer improved safety and dosing convenience over emerging small-molecule NK3R drugs.
4. Broader Pipeline and Funding Position
AbCellera holds approximately $700 million in cash and committed funding with an annual burn rate near $120 million, enabling plans for five clinical programs including second pipeline candidate ABCL575—targeting OX40 ligand—with a data update expected by year-end 2026 and potential partnering post-Phase I.